CurrentCignaPolicy N/A

Vecamyl Prior Authorization Policy

Prior authorization policy for Vecamyl (mecamylamine hydrochloride tablets) for prescription benefit coverage, specifying medical necessity criteria for FDA‑approved indications (moderately severe to severe essential hypertension and uncomplicated malignant hypertension), noncovered uses, and approval duration.

Policy Summary

PayerCigna

PolicyVecamyl Prior Authorization Policy

Policy CodePolicy N/A

Change Typeclarified

Effective DateN/A

Next Review DateN/A

Key ActionPrior Authorization is recommended for prescription benefit coverage of Vecamyl; approvals are provided for 1 year for eligible indications meeting the policy criteria.

SourceLink

POLICY UPDATE CHANGES

Annual Revision with Summary of Changes = No criteria changes.

2Covered Indications

1Not Covered Listed

4Required prior classes tried

Coverage Summary & Criteria

FDA-Approved Indications

Vecamyl is covered as medically necessary when the following criteria are met for the specified FDA-approved indications; approvals are for 1 year.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Essential Hypertension, Moderately Severe to Severe

A: Patient has tried four antihypertensive therapies, each from different pharmacologic classes (e.g., diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers [as single-entity or as combination products]).
B
- i: Patient has had inadequate efficacy.
- ii: Patient has experienced adverse event(s) severe enough to warrant discontinuation of this agent, according to the prescriber.

Uncomplicated Malignant Hypertension

A: Patient has tried four antihypertensive therapies, each from different pharmacologic classes (e.g., diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers [as single-entity or as combination products]).
B
- i: Patient has had inadequate efficacy.
- ii: Patient has experienced adverse event(s) severe enough to warrant discontinuation of this agent, according to the prescriber.

Conditions Not Covered

Vecamyl is considered not medically necessary for any other uses including the listed condition(s).

Not Medically Necessary Uses: Tourette Syndrome — mecamylamine is considered not medically necessary due to limited data and a clinical trial showing lack of efficacy for tics and the total spectrum of symptoms associated with Tourette Syndrome.

Prior Authorization & Documentation Requirements

Prior Authorization

Prior authorization required

Approvals provided for 1 year for eligible indications meeting policy criteria.

Documentation Required

Document trials of four antihypertensive classes

Provider must document trials of four antihypertensive therapies each from different pharmacologic classes and, for each agent, either inadequate efficacy or adverse events warranting discontinuation.

Evidence & Guideline References

Prescribing information: Vecamyl tablets [prescribing information], Vyera; November 2022.

Guideline citation: 2017 ACC/AHA Hypertension Guideline (Whelton et al. Hypertension. 2018;71:e13-e115).

Tourette trial: Multicenter double-blind placebo-controlled study showing mecamylamine not effective for Tourette's Disorder (Silver et al. 2001).

Background

Vecamyl (mecamylamine) is a nicotinic parasympathetic ganglionic blocker indicated for moderately severe to severe essential hypertension and uncomplicated malignant hypertension.

The 2017 ACC/AHA guideline notes that although multiple classes of antihypertensive agents are available, Vecamyl is not suggested as a primary or secondary agent; initial and secondary choices are among four classes: thiazide-type diuretics, calcium channel blockers, ACE inhibitors, or ARBs.

A clinical trial has shown that mecamylamine is not effective for Tourette Syndrome (noted as a condition considered not medically necessary due to limited data and lack of efficacy).